The recently completed ENCODE project is a new source of information on metabolic activity, unveiling knowledge about evolution and similarities among species, refuting the myth that most DNA is "junk" and has no actual function. With this expansive resource comes a challenge: integrating these new layers of information into our current knowledge of single-nucleotide polymorphisms and previously described metabolic pathways with the aim of discovering new genes and pathways related to human diseases and traits. Further, we must determine which computational methods will be most useful in this pursuit. In this paper, we speculate over the possible methods that will emerge in this new, challenging field. Genet Epidemiol 38:275-280, 2014.
Introduction
The ENCODE project [Feingold et al., 2004] , launched in 2003, right after the announcement of the end of the Human Genome project [Lander et al., 2001; Venter et al., 2001] , is a global effort to identify and understand functional elements related to the human genome. A pilot phase was first performed [Birney et al., 2007] , 1% of the genome was selected as a target, with half of the regions chosen according to well characterized genes or other functional elements [Feingold et al., 2004] , and the other half selected due to observed conservation in other species, indicating functional importance [Blakesley et al., 2004] . The targeted species were chimpanzee, macaque, mouse, rat, dog, and cow, with chicken, frog, and zebrafish included soon after.
Given the complexity of the task at hand, several groups were assigned specific tasks. The GENCODE consortium [Harrow et al., 2006] , for instance, aimed at identifying and annotating all protein-coding genes. After their work was reevaluated, new coding regions came up, along with falsepositives and false-negatives. During the pilot phase, however, new knowledge about transcription, regulation of transcription, replication, chromatin architecture, and genomic domains, and about evolutionary constraint and population variability was found [Birney et al., 2007] , motivating the continuation of the effort across the genome. An ensemble of Supporting Information is available in the online issue at wileyonlinelibrary.com. * Correspondence to: Vinicius Tragante, MSc, Heidelberglaan 100 STR 1. 304, 3584 CX, Utrecht, The Netherlands. Tel: +31 88 75 68790; Fax: +31 88 75 55423; E-mail: v.tragante@umcutrecht.nl new technologies and computational tools emerged therefore to speed up the process, allowing for rapid data production at full-genome scale.
Five years later, an ensemble of 30 articles was released jointly [ENCODE Project Consortium, 2012] , presenting new methods, results and knowledge from the ENCODE project. In this collective effort of 32 institutes and over 400 researchers, a total of 147 different cell types have been studied using a wide variety of experimental assays, such as ChIPseq, DNase-seq, FAIRE-seq, and RNA-seq. It was revealed that an actual activity could be attributed to around 80% of the human genome, refuting once and for all that most of the human DNA is "junk" [Ecker et al., 2012] . Between coding regions, there are promoters, enhancers and sequences converted into RNA, but not into proteins, and are suspected to play regulatory roles. This new source of information can be key in the design and interpretation of genome-wide association studies (GWAS), by delimiting and defining regions considered for evaluation given their activity information.
Current microarray and sequencing technologies go beyond expression levels of single-nucleotide polymorphism (SNPs) and genes by identifying characteristics such as copy number variations (CNVs), methylations, and microRNAs [Chen et al., 2008; Gunderson et al., 2005; Schumacher et al., 2006; Yau and Holmes, 2008] . This newly developed technology allowed for techniques such as GWAS, studies that proved to be a milestone in the discovery of mutations related to complex diseases and human traits. The idea of thousands of single nucleotides being analyzed at the same time seemed unlikely 20 years ago, but became a reality in the early 2000s [Fan et al., 2003] . Findings from GWAS, however, did not meet the expectations of a segment of the scientific community [Visscher et al., 2012] , in part due to the lack of knowledge regarding the network and dynamics of processes in molecular biology [Li et al., 2012] . In fact, most of the diseasecausing variants found thus far have modest effect sizes, with odds ratios varying between 1.1 and 1.5 [Anderson et al., 2011] , and the sum of these effects fails to explain the majority of the heritability of many complex traits and diseases [Eichler et al., 2010] . Power calculations from GWAS results indicate that extremely large cohorts would be necessary to identify all variants related to a specific trait. Simulations in silico required 32 million individuals in order to identify a variant with an OR of 1.01 [van der Net et al., 2009] , in the current genome-wide approach. For economical and logistical reasons, a cohort this size likely will not exist in the near future.
One of the possible reasons for the suboptimal findings is the Bonferroni correction applied to results [Bland and Altman, 1995; Bonferroni, 1936] . According to the Bonferroni theory, one must try to avoid the finding of significant results by chance alone with a division of the significance threshold (usually P = 0.05) by the number of tests being performed. This means that, in a common genome-wide scan with ß1.000.000 loci, the significance level needed to claim a positive association is six orders of magnitude lower. Besides, a recent study [Schaub et al., 2012] shows that most GWAS findings so far are not the lead SNPs of the loci related to diseases, but in linkage disequilibrium (LD) with the real lead SNP, which is in most times not genotyped or imputed in GWAS studies, due to their limited comprehensiveness. This study, by Schaub et al. [Schaub et al., 2012] , is one of the first to already apply ENCODE data in GWAS studies, demonstrating its power to fine-tune and improve findings from genome-wide studies. Besides, one can employ ENCODE data to add functional evidence to a GWAS finding, or support a claim that a locus, although not genome-wide significant, is associated with a disease. In GWAS studies, it is common that a few signals do not pass the strict Bonferronicorrected threshold, although having a considerably low P value (for instance, in below P < 1 × 10 -6 ), and those signals cannot be claimed significant. The case is stronger to claim an association if such signal is involved in regulation or suffers epigenetic changes.
On the other hand, if we consider the known pathobiology of diseases studied so far, it would not be necessary to test many unrelated chromosomal regions. One example of a known pathobiology dataset is Gene Ontology [Ashburner et al., 2000; Blake et al., 2013] , a collaborative effort to standardize names and functions to identified biological processes, cellular components and molecular functions in different species.
ENCODE emerges as a new source for increasing the knowledge already acquired with Gene Ontology, by allowing to narrow the search for markers that correspond to specific functions (for example transcription factor binding sites of specific genes, as described by Cowper-Sal lari et al. [Cowper-Sal lari et al., 2012]), and therefore reducing the stringency of the multiple-testing correction.
In order to better link the knowledge obtained by Gene Ontology and similar efforts to traits and diseases, pathway analysis methods (also called pathway-wide association analyses or gene set enrichment analysis [Boyles et al., 2009; Califano et al., 2012] ) were developed, taking into consideration topologically related events that cluster under the same regulatory network [Califano et al., 2012] . These networks, however, are poorly characterized, lacking dynamic and multiscale information. Context-specific gene regulatory networks [Kim et al., 2007] would then come as an evolution of the current known pathways, by integrating information on binding sites, CNVs, and epigenetics, among others, in order to create a more complete and dynamic picture of the complex processes of the human body [Li et al., 2012] .
The ENCODE data can potentially contribute significantly to our understanding of pathways. Rich datasets of different layers of information are available freely via the UCSC genome browser [Karolchik et al., 2003; Rosenbloom et al., 2012] . However, methods to process and integrate these datasets are emerging, and a "gold standard" method has yet to be described.
In recent years, it has become solid knowledge that multiple complex networks of regulation and expression are involved in the different cellular processes, and this field gains momentum with the ENCODE data. Computational solutions involving extensive usage of traditional statistical methods take into consideration different layers of biological information in evaluating the roles of different genomic features and products in human functions and diseases. These data are similar in scope as that produced by the ENCODE project, showing that the field can benefit from these new sources of data.
Most methods developed so far to deal with multiple layers of biological information use statistical method, with a vast literature on the subject [Gao et al., 2004; Hotelling, 1936; Kutalik et al., 2008; Li et al., 2012; Li and Chan, 2009; Mankoo et al., 2011; Sun, 2012; Witten and Tibshirani, 2009 ]. We focus here on reviewing the role of machine learning as a complementary approach for the analysis of complex biological data. In particular, we introduce evolutionary computation as a machine learning approach that is particularly well suited for big data problems in the biological and biomedical sciences.
Machine Learning
Machine learning is a subfield of Artificial Intelligence, dedicated to studying methods and algorithms capable of tasks considered "intelligent" if done by humans. In most cases, these algorithms achieve results by "learning" a number of observations from real-world data and then identifying patterns from these observations. Examples of fields where machine learning techniques are employed successfully are in automation, oil industry, chemical process control, and in biology, for gene identification [Hayes and Borodovsky, 1998 ], bioinformatics [Baldi and Brunak, 2001] and diagnosis [Dreiseitl et al., 2001] .
In fact, machine learning played an important role already in the generation of ENCODE data. Yip et al. [Yip et al., 2012] use supervised and unsupervised methods to predict enhancers and transcription factors; the main ENCODE paper [ENCODE Project Consortium, 2012] uses selforganized maps (SOMs) to cluster regions based on common characteristics; the SOMs show correlation with Gene Ontology terms, based on histone patterns.
Machine learning can be leveraged for recognizing suitable pathways, and we draw special attention to support vector machines (SVMs) [Steinwart and Christmann, 2008] , one of the most employed machine learning algorithms thus far in human genetics.
SVMs are binary linear classifiers that build hyperplanes (subdivisions of the solution space) that separate two different categories of objects, instances or observations. In an application to genetics, this could be relevant and nonrelevant elements of a specific regulatory network. The algorithm is extensively described in the literature [Hearst et al., 1998; Steinwart and Christmann, 2008] , and numerous variations on the basic concept have been described in the last decade. They all share the "kernel trick," performing nonlinear evaluations using kernels of higher-dimensional space, making it easier to separate between classes without high computational cost. In our case, SVMs should be capable of adjusting a set of hyperplanes that successfully separates the ensemble of genes, cistromes, and epigenomes that are not related to a given metabolic process or disease. Several studies make use of kernel learning for genetic purposes [Yu et al., 2010; Gönen and Alpaydın, 2011; Hamid et al., 2011] .
SVMs have been successfully applied in the context of inference with ENCODE data. Arvey et al. [Arvey et al., 2012] trained SVMs to model transcription-factor binding regions using DNA sequence signal, histone modifications, and DNase accessibility. The authors concluded from the results that a single motif is not enough to describe TF binding profiles, but much more information can be captured by SVM models.
We see a parallel in Multiple-Instance Learning, a subfield of Machine Learning in which the goal is to classify sets of instances grouped into "bags," with information only on the bag classification. Individual instances are not classified; if only one instance in a "bag" is positive, the whole bag is classified as positive. In a human genetics application, this would mean that a pathway with a SNP, gene, cistrome, or epigenome associated to a particular process or disease would make the whole pathway suitable for evaluation. Similarly, pathways without associated signals do not take part in further studies. SVM methods are successful in Multi-Instance Learning [Andrews et al., 2002; Drucker et al., 1999; Fu et al., 2011] .
Evolutionary Computing
Evolutionary computing (EC) is another subfield of Artificial Intelligence, which relies on the evolutionary theory of trial and error for success [Eiben and Smith, 2008] , aiming at the best adaptation to an environment (fitness is the word in the field). The basic premise is that a solution to a particular problem can be fragmented into small pieces, and different sets of solutions can be mixed and matched to form an ideal solution to a problem. Each set of solutions is said to be an "individual" in a "population" of solutions, and new sets of solutions are formed via methods such as "cross-over," "mutation," or "migration," which are analogous to the genetic concepts of those terms.
The best-known subfields of EC are genetic programming (GP) and genetic algorithms (GAs). GAs mimic the behavior of natural evolution, by evolving solutions according to their "fitness" to the problem at hand. Each individual in each generation corresponds to a mathematical value that represents a solution. GP is a specialization of GAs, in which parameters and functions of an algorithm are possible solutions, and the resulting program fits best to the problem studied. An analogy can be traced to fixing a car, while GAs aim at the right steps in order to fix it, GP aims at the right set of tools that can perform the right steps, which can then be considered a previous step in solving the problem.
Multiobjective GAs [Konak et al., 2006; Murata and Ishibuchi, 1995] are a special class of evolutionary algorithms built to deal with multiple layers of optimization. One key concept in this field is the Pareto Frontier, based on the Pareto efficiency theory [Vlennet et al., 1996] . The theory states that there is a point in optimization in which no improvement happens without worsening another objective. In multilayer pathway analysis this means adjusting the number of relevant SNPs, cistromes, or epigenomes that are relevant to a given network and eliminating from the evaluation those that are not related to such network (a high-level fluxogram of such idea can be seen on Fig. 1) . Using data obtained from ENCODE, fewer statistical tests would be necessary to determine a specific set of genes needed to maximize statistical power and as a result, the threshold correction for multiple testing would be less strict.
GP is an automated computational discovery tool that is inspired by Darwinian evolution by natural selection [Banzhaf et al., 1997; Koza, 1992] . The goal of GP is to "evolve" computer programs to solve complex problems. One accomplishes this by first generating or initializing a population of random computer programs that are composed of the basic building blocks needed to solve or approximate a solution to the problem. For genetic association studies, this might be a list of single-nucleotide polymorphism or single-base changes, other important attributes such as age and gender along with a list of useful mathematical functions. Each randomly generated program is evaluated and the good programs are selected, recombined, and mutated to form new computer programs. This process of selection based on fitness and recombination to generate variability repeats until a best program or set of programs emerge. GP and its many variations have been applied successfully in a wide range of different problem domains including bioinformatics (e.g., [Fogel and Corne, 2002] ) and genetic analysis . GP is an attractive approach to the genetic analysis problem because it is inherently flexible, stochastic and parallel. These features are necessary in a computational analysis strategy when the problem is complex and it is not clear to the modeler what a valid solution looks like.
Apart from the parameter setting of the GA/GP, a welldefined fitness function represents a bigger chance of success.
Genetic Epidemiology, Vol. 38, No. 4, 275-280, 2014 Figure 1. In a setup with a GA integrated into the analyses, different datasets are presented to the GA, and through the generations an ideal combination of subsets of each of those datasets is formed, in order to generate a suitable dataset for pathway analyses.
The fitness function must evaluate as precisely as possible the individuals, in order to keep successfully the best solutions to the problem. Recently, novel ways of defining the fitness function have been described, under the term interestingness [Geng and Hamilton, 2006 ]. In some domains, it is not clear which results to expect, and with metrics such as surprisingness (results that contradict prior knowledge), peculiarity (results that have no relatedness with other results), or applicability (results that enable decision making in the domain), new knowledge can be discovered. A successful example of the use of such metrics can be found in , in which a multi-objective GA used interestingness as one of the objectives of the fitness function to detect complex interactions among different genetic factors, and found models that helped improve the classification accuracy of patients.
One of the challenges of modeling genetic effects in genome-wide data sets is that there are an effectively infinite number of possible models. This is especially challenging when good models cannot be predicted from lower order genetic effects. This can occur when the genetic architecture of the trait is determined by nonadditive gene-gene and gene-environment interactions. GP is an effective tool for this problem because of its parallel and stochastic nature. Further, it is possible to incorporate expert knowledge into GP to help guide the search through the effectively infinite search space. This can be accomplished through a multi-objective fitness function [Moore et al., 2009] , sensible initialization of the set of initial models [Payne et al., 2010] , or Pareto optimization that rewards models with attributes representing genes that might be biological or statistically important . These approaches attempt to discovery and characterize models in a manner that is much more closely aligned with how humans solve problems. They are thus squarely under the umbrella of artificial intelligence and machine learning.
GP and GA are well-suited for these types of problems. GP is a good approach when the knowledge in the domain is incomplete, because it provides a flexible way to represent solutions to a problem, and parameters and settings can be defined by the algorithm itself, until an optimal solution is found. GA has an intrinsic stochastic search aspect that is needed for big data, where the solution space is effectively infinite, and exploring its entirety is not computationally feasible.
We illustrate the possibilities that a combined GP + GA approach is capable of with a theoretical example. GWA studies on coronary artery disease and myocardial infarction (CAD/MI) have identified so far around 50 loci associated with the phenotype [Deloukas et al., 2012; Roberts and Stewart, 2012; Schunkert et al., 2011] . However, an extra 100 loci may be involved with CAD/MI according to the most recent meta-analysis on the trait, but failed to reach the significance threshold of P < 5 × 10 -8 (Supporting Information  Table S9 of Deloukas et al. [2012] ). We can add evidence to these loci by evolving a GP using a set of ENCODE data sources in a binary coding setup. In other words, each source of information is an allele from an individual that represents a solution for the problem (in GPs and GAs, an individual is a possible solution to a problem, a metaphor to the genetic information from living beings). The system will evolve to decide whether, for instance, transcription factor binding sites in kidney or the H3k27ac acetylation in bone is necessary information to classify each locus of the list as associated or not. The strategy follows up with a GA that takes the information coming from the GP and evolves sets of loci in order to identify if those loci are associated with the trait. The evaluation metric (fitness) is the result of an equation that weighs the evidence sources by their strength of association, in most cases P values; the value that maximizes the function corresponds to the set of loci that most associate with CAD/MI. For the above explained reasons, we believe that GP and GA offer an opportunity to successfully integrate different sources of information provided by ENCODE and increase the knowledge in the field.
Discussion
In the recent years, the scientific community has managed to bring to surface an immense amount of knowledge on human genetics. On the one hand, with the development of new massively parallel sequencing technologies, such as DNA microarrays, ChIP-seq, DNase-seq, FAIRE-seq, and RNA-seq; on the other hand with the development of new computational methods to deal with these huge sources of information, such as GWAS, pathway analyses, and expression analyses.
The ENCODE project, one of the drivers and, at the same time, one of the results of all these efforts, offers the possibility of a new perspective on the mechanisms and pathways related to metabolic processes. Cistromes and epigenomes are also involved in metabolic processes and diseases, and this knowledge was not available until a few years ago. With this wealth of new information, though, comes the challenge of integrating and identifying relevant subprocesses for each regulatory network or metabolic process. The time has come to develop techniques that can make the most of all this information, in an integrated fashion.
We believe that Machine Learning is bound to play a key role in this new, challenging task. Machine learning techniques have been useful in a number of classification and optimization tasks in different fields, and have as advantage the possibility of customization and adaptation to changes in the landscape of the problem. Particularly, applications of SVMs, GAs, and GP, as described in previous sessions, seem suitable for the task of integrating results from different related genetic experiments and producing a detailed result, taking into consideration expression, regulation, and enhancement values from DNA markers throughout the genome.
Such combination of ENCODE data and multilayer analysis techniques may be able to link histone modifications to specific diseases, for example, or a set of RNA transcripts that are not converted into proteins but regulate blood pressure; or histone modifications that associate with SNPs that did not reach genome-wide significance for CAD/MI, and therefore add up to the claim that such SNPs are significant for the trait. The possibilities are many, and we are just scratching the surface.
The ENCODE data, though quite broad in scope, must be incorporated into the current body of knowledge of complex human traits and disease. Doing so will improve study design, such that the number of genes tested is reduced, smaller sample sizes will still provide sufficient power, and implicated networks or pathways will be well described. Fundamentally, our goal must be to find a way to integrate these layers of in-formation and better understand the underlying architecture of human processes and disease.
